Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study

@article{Tyring2001FamciclovirFO,
  title={Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study},
  author={Stephen K. Tyring and Reinhard Engst and Christine L. Corriveau and Nicole Robillard and Sylvie Trottier and S Van Slycken and Rachel A Crann and Leslie A. Locke and Robin L. Saltzman and Alan G. Palestine},
  journal={British Journal of Ophthalmology},
  year={2001},
  volume={85},
  pages={576 - 581}
}
AIMS To compare the efficacy and safety of famciclovir with aciclovir for the treatment of ophthalmic zoster. METHODS Randomised, double masked, aciclovir controlled, parallel group in 87 centres worldwide including 454 patients with ophthalmic zoster of trigeminal nerve (V1) comprised the intent to treat population. Oral famciclovir 500 mg three times daily or oral aciclovir 800 mg five times daily for 7 days. Assessments included day 0 (screening), days 3 and 7 (during treatment), days 10, 14… 

EFFICACY AND SAFETY OF TABLET FAMCICLOVIR 500 MG (PENVIR) IN THE TREATMENT OF OCULAR HERPES

Objective: To assess the efficacy and safety of oral tablet famciclovir 500mg in the management of Ocular Herpes. Patients and Methods: Patients diagnosed with ocular herpes were enrolled as per

Effect of Early Treatment of Acyclovir and Famciclovir on Post - herpetic Trigeminal Neuralgia

TLDR
Antiviral treatment, either with acyclovir or famciclovir, can be used to reduce acute pain of herpes zoster and postherpetic neuralgia and can also shorten the duration of PHN.

Antivirals for Management of Herpes Zoster Including Ophthalmicus: A Systematic Review of High-Quality Randomized Controlled Trials

TLDR
Evidence from quality trials have shown significant reduction in risk of pain with valaciclovir and famciclovIR for management of herpes zoster including ophthalmicus.

Treatment of herpes zoster.

TLDR
There is no convincing evidence that antiviral medication reduces the risk of PHN, and these drugs should be prescribed to all patients at the first signs of ophthalmic HZ, irrespective of age or severity of symptoms.

Visual prognosis in immunocompetent patients with herpes zoster ophthalmicus.

TLDR
Functional vision was retained in all ophthalmic zoster patients referred to the ophthalmologist in the acute phase of the disease by vigorous antiviral treatment and adequate prevention of corneal exposure.

Herpes zoster antivirals and pain management.

Herpes zoster and postherpetic neuralgia

TLDR
PHN can be difficult to treat; studies have shown that valacyclovir or famciclovir started within 72 h of rash onset, amitriptyline started within 48 h of Rash onset and epidural local anesthetic with steroid given within the first 2 months may decrease the incidence of PHN.

Herpes Zoster: Diagnostic, Therapeutic, and Preventive Approaches

  • M. Bader
  • Medicine
    Postgraduate medicine
  • 2013
TLDR
Varicella-zoster virus vaccine and early treatment with either famciclovir or valacyclovir are the only measures proven to prevent post-herpetic neuralgia (PHN), which is the most common and debilitating Herpes zoster complication.

Herpes zoster ophthalmicus and its varied clinical manifestations

TLDR
HZO take a longer course in patients with abnormal HbA1c values, however diagnosis can be established with elisa, tzank smear in cases with varied clinical manifestation.
...

References

SHOWING 1-10 OF 24 REFERENCES

Oral acyclovir in the treatment of herpes zoster in general practice.

TLDR
Acyclovir reduced the extent and duration of the rash, the spread of the Rash to adjacent dermatomes and the incidence of disseminated lesions, and it shortened the period of new lesion formation and reduced the occurrence of ulceration in acute herpes zoster and postherpetic neuralgia.

Management of ophthalmic zoster

TLDR
Although limited by poor systemic absorption, oral acyclovir appears to have a beneficial effect on herpes zoster ophthalmicus, and until alternative formulations or better drugs are developed its use in all cases is justified.

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

TLDR
Famciclovir, a new antiviral agent, was approved for marketing by the Food and Drug Administration in June 1994 for the management of acute herpes zoster and its effect on postherpetic neuralgia remains controversial.

Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement.

TLDR
Postherpetic neuralgia (PHN) was more likely in patients over 80 and in those who scored their pain highly at presentation and in patients who developed PHN, and no other associations between the parameters studied were found.

Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation.

TLDR
Oral acyclovir provides effective prophylaxis against reactivation of herpes simplex virus among severely immunosuppressed patients able to take orally administered drugs and was associated with significantly more rapid marrow engraftment in patients receiving methotrexate.

Oral acyclovir in acute herpes zoster

TLDR
It is suggested that in psychiatrically vulnerablewomen gynaecological symptoms might induce emotionalsymptoms or that chronic difficulties might induce psychiatric disorders that could make women more likely to pay attention to gynaECological symptoms, or find them distressing, or regard them as abnormal.

Pharmacokinetics of acyclovir after intravenous and oral administration.

TLDR
Acyclovir half-life (T1/2 beta) and total body clearance (Cltot) are influenced significantly by renal function, and dosage adjustments should be made for patients with impaired renal function; therefore dosage adjustments based on Clcr will compensate for age-related changes in renal function.

Antiviral chemotherapy: New directions for clinical application and research

Management of Genital Herpes G.J. Mertz Subclinical Shedding of HSV: Its Potential for Reduction by Antiviral Therapy L. Corey, et al. Famciclovir: Efficacy in Zoster and Issues in the Assessment of